Preferred Name |
Alirocumab |
|
Synonyms |
ALIROCUMAB Alirocumab Praluent |
|
Definitions |
A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, alirocumab targets, binds to and inhibits the activity of PCSK9. This prevents the binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C174849 |
|
CAS_Registry |
1245916-14-6 |
|
code |
C174849 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
Contributing_Source |
CTRP FDA |
|
DEFINITION |
A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, alirocumab targets, binds to and inhibits the activity of PCSK9. This prevents the binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver. |
|
Display_Name |
Alirocumab |
|
FDA_UNII_Code |
PP0SHH6V16 |
|
FULL_SYN |
ALIROCUMAB Alirocumab Praluent |
|
label |
Alirocumab |
|
NCI_Drug_Dictionary_ID |
811355 |
|
NCI_META_CUI |
CL1412123 |
|
Preferred_Name |
Alirocumab |
|
prefixIRI |
Thesaurus:C174849 |
|
Semantic_Type |
Pharmacologic Substance |
|
subClassOf |